149 related articles for article (PubMed ID: 16317268)
1. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
[TBL] [Abstract][Full Text] [Related]
2. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
Chiesa MD; Buti S; Tomasello G; Negri F; Buononato M; Brunelli A; Lazzarelli S; Brighenti M; Donati G; Passalacqua R
Tumori; 2007; 93(3):244-7. PubMed ID: 17679458
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Bamias A; Papamichael D; Syrigos K; Pavlidis N
J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Yamao T; Shirao K; Matsumura Y; Muro K; Yamada Y; Goto M; Chin K; Shimada Y
Ann Oncol; 2001 Dec; 12(12):1729-35. PubMed ID: 11843251
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Hamaguchi T; Shirao K; Ohtsu A; Hyodo I; Arai Y; Takiuchi H; Fujii H; Yoshida M; Saito H; Denda T; Koizumi W; Iwase H; Boku N;
Gastric Cancer; 2011 Aug; 14(3):226-33. PubMed ID: 21503598
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
Yamao T; Ohta K; Ohyama S; Ishihara S; Chin K; Maruyama M; Takahashi T; Nakajima T
Jpn J Clin Oncol; 2004 May; 34(5):255-61. PubMed ID: 15231860
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
Boku N; Ohtsu A; Shimada Y; Shirao K; Seki S; Saito H; Sakata Y; Hyodo I
J Clin Oncol; 1999 Jan; 17(1):319-23. PubMed ID: 10458249
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Baek JH; Kim JG; Jeon SB; Chae YS; Kim DH; Sohn SK; Lee KB; Choi YJ; Shin HJ; Chung JS; Cho GJ; Jung HY; Yu W
Br J Cancer; 2006 May; 94(10):1407-11. PubMed ID: 16641916
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Yilmaz U; Oztop I; Alacacioglu A; Yaren A; Tarhan O; Somali I
Chemotherapy; 2006; 52(5):264-70. PubMed ID: 16873996
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
17. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Zhao WY; Chen DY; Qi Q
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
[TBL] [Abstract][Full Text] [Related]
18. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
